Results 141 to 150 of about 22,142 (188)

Healthcare resource utilization analysis in newly diagnosed mantle cell lymphoma: resource alleviation with adoption of the TRIANGLE ibrutinib regimen without autologous stem cell transplantation. [PDF]

Ann Hematol
Wißkirchen J, Rogmann NS, Greiling M, Ries F, Ohler A, Hess G, Osygus J.   +6 more
europepmc   +1 more source

A Case of Pseudo-Richter Transformation Following Zanubrutinib Discontinuation in CLL. [PDF]

Mediterr J Hematol Infect Dis
Laurenti L, Quaranta T, Tomasso A, Stirparo L, Abbate PL, Bakacs A, Cappoli N, Di Napoli A, Efremov D, Bellisario F, Gattei V, Caldarella C, Calcagni ML, Autore F, Innocenti I.   +14 more
europepmc   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study. [PDF]

Br J Haematol
Zelmat Y, Ysebaert L, Gautier P, Sommet A, Lafaurie M, Despas F.   +5 more
europepmc   +1 more source

First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs. [PDF]

Clinicoecon Outcomes Res
Perrone V, Innao V, Mazzoni S, Cappuccilli M, Andretta M, Bartolini F, Chinellato A, Dell'Orco S, Ferrante F, Lombardi R, Pagliaro R, Ubertazzo L, Valpondi P, Degli Esposti L.   +13 more
europepmc   +1 more source

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. [PDF]

Oncol Ther
Ermann DA, Stephens DM, Wang X, Varghese I, De Souza H, Sheetz C, Fu Q, Maglinte GA, Williams R, Seymour EK, van Beuge D, Shadman M, Jacobs R.   +12 more
europepmc   +1 more source

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up. [PDF]

Adv Ther
Shadman M, Munir T, Xu S, Yang K, Mohseninejad L, Guthrie G, Hirata J, Lefebure M, Williams R, Tam CS.   +9 more
europepmc   +1 more source

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. [PDF]

Hemasphere
Belada D, Gardner FP, de Oliveira AC, Sancho JM, Lomaia E, Wright D, Turgut M, Martynova E, Lázár Z, Anz B, Wang MC, Legiec W, Opat S, Pailden J, Peltier HM, Marturano E, Dean JP, Flinn IW.   +17 more
europepmc   +1 more source

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy. [PDF]

Res Pract Thromb Haemost
Kartika T, Buitrago L, Li J, Cunningham-Rundles C, Coller BS.   +4 more
europepmc   +1 more source

Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies. [PDF]

Mol Ther Oncol
Ni Q, Rui L.
europepmc   +1 more source

PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia. [PDF]

Blood Adv
Qi J, Li W, Dheenadayalan RP, Yosifov DY, Drewes C, Wist M, Wieczorek M, Schmid V, Hobeika E, Gao X, Endres S, Schneider C, Riecke A, Barth H, Gierschik P, Siebert R, Tausch E, Stilgenbauer S, Jebaraj BMC.   +18 more
europepmc   +1 more source